|
|
Post by lakers on Feb 12, 2016 18:21:21 GMT -5
George A. Gaitanaris, M.D., Ph.D.
Vice President, Science and Chief Scientific Officer
http://investor.omeros.com/phoenix.zhtml?c=219263&p=irol-govBio&ID=203447
George A. Gaitanaris, M.D., Ph.D. has served as our vice president, science since August 2006 and as our chief scientific officer since January 2012. From August 2003 to our acquisition of nura, inc. in August 2006, Dr. Gaitanaris served as the chief scientific officer of nura, a company that he co-founded and that developed treatments for central nervous system disorders. From 2000 to 2003, he served as president and chief scientific officer of Primal, Inc., a biotechnology company that was acquired by nura in 2003. Prior to co-founding Primal, he served as staff scientist at the National Cancer Institute. Dr. Gaitanaris received his Ph.D. in cellular, molecular and biophysical studies and his M.Ph. and M.A. from Columbia University and his M.D. from the Aristotelian University of Greece.
Andrea Leone-Bay is now chief scientific officer of RLS since Oct 2015. Normally, CMO would be used in place of chief scientific officer.
|
|
|
|
Post by nylefty on Feb 12, 2016 19:31:24 GMT -5
George A. Gaitanaris, M.D., Ph.D. Vice President, Science and Chief Scientific Officer http://investor. omeros.com/phoenix.zhtml?c=219263&p=irol-govBio&ID=203447 George A. Gaitanaris, M.D., Ph.D. has served as our vice president, science since August 2006 and as our chief scientific officer since January 2012. From August 2003 to our acquisition of nura, inc. in August 2006, Dr. Gaitanaris served as the chief scientific officer of nura, a company that he co-founded and that developed treatments for central nervous system disorders. From 2000 to 2003, he served as president and chief scientific officer of Primal, Inc., a biotechnology company that was acquired by nura in 2003. Prior to co-founding Primal, he served as staff scientist at the National Cancer Institute. Dr. Gaitanaris received his Ph.D. in cellular, molecular and biophysical studies and his M.Ph. and M.A. from Columbia University and his M.D. from the Aristotelian University of Greece. Andrea Leone-Bay is now chief scientific officer of RLS since Oct 2015. Normally, CMO would be used in place of chief scientific officer. I'm not sure what you're trying to suggest, but CMO's have MD degrees and Leone-Bay doesn't have one. |
|
|
|
Post by lakers on Feb 12, 2016 20:07:41 GMT -5
Georgie has MD. Omeros gave him the CSO title. Throughout several reincarnations, Omeros has used CSO instead. Ditto RLS, a spinoff.
|
|
|
|
Post by sccrbrg on Feb 12, 2016 20:36:29 GMT -5
Georgie has MD. Omeros gave him the CSO title. Throughout several reincarnations, Omeros has used CSO instead. Ditto RLS, a spinoff. So because they used the same title it must be RLS? That's so far fetched I can't even call it a stretch. I think RLS is really a google spin-off because they both have websites... |
|
|
|
Post by lakers on Feb 13, 2016 2:54:36 GMT -5
Georgie has MD. Omeros gave him the CSO title. Throughout several reincarnations, Omeros has used CSO instead. Ditto RLS, a spinoff. So because they used the same title it must be RLS? That's so far fetched I can't even call it a stretch. I think RLS is really a google spin-off because they both have websites... You didn't read the entire thread regarding Omeros. Take your time before passing judgment. There were a lot more that pointed to Omeros direction. |
|
|
|
Post by jpg on Feb 13, 2016 3:22:06 GMT -5
So because they used the same title it must be RLS? That's so far fetched I can't even call it a stretch. I think RLS is really a google spin-off because they both have websites... You didn't read the entire thread regarding Omeros. Take your time before passing judgment. There were a lot more that pointed to Omeros direction. Even if it is Omros: what difference does it make to Mannkind's financial viability? They got 0$ upfront and we have no clue as to when they will get meaningful $s. |
|
|
|
Post by peppy on Feb 13, 2016 7:00:33 GMT -5
George A. Gaitanaris, M.D., Ph.D. Vice President, Science and Chief Scientific Officer http://investor. omeros.com/phoenix.zhtml?c=219263&p=irol-govBio&ID=203447 George A. Gaitanaris, M.D., Ph.D. has served as our vice president, science since August 2006 and as our chief scientific officer since January 2012. From August 2003 to our acquisition of nura, inc. in August 2006, Dr. Gaitanaris served as the chief scientific officer of nura, a company that he co-founded and that developed treatments for central nervous system disorders. From 2000 to 2003, he served as president and chief scientific officer of Primal, Inc., a biotechnology company that was acquired by nura in 2003. Prior to co-founding Primal, he served as staff scientist at the National Cancer Institute. Dr. Gaitanaris received his Ph.D. in cellular, molecular and biophysical studies and his M.Ph. and M.A. from Columbia University and his M.D. from the Aristotelian University of Greece. Andrea Leone-Bay is now chief scientific officer of RLS since Oct 2015. Normally, CMO would be used in place of chief scientific officer. chief scientific officer of nura, a company that he co-founded and that developed treatments for central nervous system disorders.
Examples include: •Parkinson's disease.
•Multiple sclerosis (MS).
•Amyotrophic lateral sclerosis (ALS).
•Alzheimer's disease.
•Huntington's disease.
•Peripheral neuropathies.
------------------------------------------------------------- Regarding receptor life sciences. It would be a ok with me if RLS was working on seizure disorder with technosphere: (Just speculation) Epilepsy:•Epilepsy is the fourth most common neurological disorder and affects people of all ages
•Epilepsy means the same thing as "seizure disorders
•A seizure is a sudden surge of electrical activity in the brain.
•A seizure usually affects how a person appears or acts for a short time.
•Many different things can occur during a seizure. Whatever the brain and body can do normally can also occur during a seizure
What happens in the brain during a seizure?
•The electrical activity is caused by complex chemical changes that occur in nerve cells.
•Brain cells either excite or inhibit (stop) other brain cells from sending messages. Usually there is a balance of cells that excite and those that can stop these messages. However, when a seizure occurs, there may be too much or too little activity, causing an imbalance between exciting and stopping activity. The chemical changes can lead to surges of electrical activity that cause seizures
|
|
|
|
Post by mindovermatter on Feb 13, 2016 7:52:27 GMT -5
You didn't read the entire thread regarding Omeros. Take your time before passing judgment. There were a lot more that pointed to Omeros direction. Even if it is Omros: what difference does it make to Mannkind's financial viability? They got 0$ upfront and we have no clue as to when they will get meaningful $s. It's rather comical that some are desperately trying to figure out who RLS is thinking that unmasking them is somehow going to save Mannkind. It is all academic. As you pointed out and I have been saying from the day the deal was announced was that the one thing Mannkind needed desperately was upfront cash and that wasn't part of the deal. So either Mannkind knows something is about to happen that will fund it (my guess is a lump sum payment from those French interlopers) or that Mannkind will be screwed and have to put itself up for sale before its cash dries up. Lakers should move on and go try to figure out where Lochness is, considering he's fond of lakes and such because at this point, it matters not one afrezza dreamboat who is behind RLS. |
|
|
|
Post by lakefox333 on Feb 13, 2016 8:56:26 GMT -5
Lakers, I always look forward to reading your posts. I appreciate your research and ideas, so do not be discouraged by some of the other posters with only opinions without any basis in fact.
|
|
|
|
Post by benyiju on Feb 13, 2016 14:22:08 GMT -5
MOM is entirely right, at this point the whole RLS whodunit is a sideshow and about as useful as the TASE scheme ended up being. The Market isn't going to give MNKD any more free rides, it's Show Me or get delisted.
|
|
|
|
Post by LosingMyBullishness on Feb 13, 2016 15:39:58 GMT -5
I do not see any parallel between TASE and RLS.
TASE was a plan to get cash without dilusion of US stocks. It did not worked out but that is often so in real life. Everyone would have cheered about the brilliance of the plan if it had succeeded. Why it did not succeed? This loophole had been used several times and Israli regulators decided that this time they play hardball. They did so basically in the last second (last day if I remember correctly) and as it seems without warning to MNKD management. 'Might' be that someone at Wall street asked them for this favour and this group was stronger than the old ties that Al had. I always thought that this was his last stunt. After that we did not hear much from him anymore.
RLS on the other hand is a private company that made a deal with MNKD that is doesnt want to disclose. A lot of private companies do not disclose anything. This is standard business practise and a good reason to stay private. Ask Ingvar Kamprad why he decided to keep IKEA private.
The only thing that these two have in common is that investors expected more of this. But I also expected the whole biotech sector to recover in Jan..
There is too much talk about RLS that neither makes this deal more transparent nor valuable to MNKD investors. Some day later this year we will know more. Not sooner.
|
|
|
|
Post by benyiju on Feb 13, 2016 16:27:02 GMT -5
I do not see any parallel between TASE and RLS. TASE was a plan to get cash without dilusion of US stocks. It did not worked out but that is often so in real life. Everyone would have cheered about the brilliance of the plan if it had succeeded. Why it did not succeed? This loophole had been used several times and Israli regulators decided that this time they play hardball. They did so basically in the last second (last day if I remember correctly) and as it seems without warning to MNKD management. 'Might' be that someone at Wall street asked them for this favour and this group was stronger than the old ties that Al had. I always thought that this was his last stunt. After that we did not hear much from him anymore. RLS on the other hand is a private company that made a deal with MNKD that is doesnt want to disclose. A lot of private companies do not disclose anything. This is standard business practise and a good reason to stay private. Ask Ingvar Kamprad why he decided t o keep IKEA private.The only thing that these two have in common is that investors expected more of this. But I also expected the whole biotech sector to recover in Jan.. There is too much talk about RLS that neither makes this deal more transparent nor valuable to MNKD investors. Some day later this year we will know more. Not sooner. IB, all I'm saying is that the Market isn't giving MNKD any more breaks and it doesn't seem impressed by jam tomorrow deals. MNKD is going to have to earn every cent of SP with real cash and/or real script growth. If and when RLS milestones come, then we'll get some movement, but at this point it doesn't really matter who RLS is. In fact, the only thing the RLS deal can do right now is hurt MNKD, if it turns out to be a smelly piece of fishy business like the TASE scheme. Pace the conspiracy theory version of the TASE fiasco, I think it failed mostly because MNKD didn't (even then) have very good prospects. If I was smarter, I would have picked up on the abundant clues that Sanofi was indeed going to dump Afrezza. The smart money did pick up on those clues, and in the end the only result of the TASE nonsense was that there were probably some Israeli investors very pissed off with Al Mann. |
|
|
|
Post by mindovermatter on Feb 13, 2016 16:39:48 GMT -5
Let me be very clear. The RLS deal is simply a proof of concept deal. RSL wants to see if TS works for one or possibly a few of their drugs. Because no one knows what milestones actually means money for MNKD, this deal is just like the other deals Mannkind struck back in 2014 that didn't have any up front money and were all based on milestone payments. To date, those two deals have amounted to nothing. So while some of you want to feel good about your investigative skills, let me remind you that the odds of Mannkind making anything from the RSL deal are very low. If RLS thought technosphere was the game changer that many of you think it is, it would have proved it by giving MNKD up front cash.
Many on here need to stop fooling yourselves. Unfortunately, it is quite obvious that you enjoy doing so.
|
|
|
|
Post by agedhippie on Feb 13, 2016 16:40:54 GMT -5
I do not see any parallel between TASE and RLS. TASE was a plan to get cash without dilusion of US stocks. It did not worked out but that is often so in real life. Everyone would have cheered about the brilliance of the plan if it had succeeded. Why it did not succeed? This loophole had been used several times and Israli regulators decided that this time they play hardball. They did so basically in the last second (last day if I remember correctly) and as it seems without warning to MNKD management. 'Might' be that someone at Wall street asked them for this favour and this group was stronger than the old ties that Al had. I always thought that this was his last stunt. After that we did not hear much from him anymore. The TASE maneuver diluted the US stock since it was ordinary common stock that was sold. It was a good plan but incredibly badly executed. |
|
|
|
Post by boytroy88 on Feb 13, 2016 18:22:09 GMT -5
I do not see any parallel between TASE and RLS. TASE was a plan to get cash without dilusion of US stocks. It did not worked out but that is often so in real life. Everyone would have cheered about the brilliance of the plan if it had succeeded. Why it did not succeed? This loophole had been used several times and Israli regulators decided that this time they play hardball. They did so basically in the last second (last day if I remember correctly) and as it seems without warning to MNKD management. 'Might' be that someone at Wall street asked them for this favour and this group was stronger than the old ties that Al had. I always thought that this was his last stunt. After that we did not hear much from him anymore. The TASE maneuver diluted the US stock since it was ordinary common stock that was sold. It was a good plan but incredibly badly executed. The TASE deal didn't work out but I don't see how it diluted the US market since there were no new shares offered. If I'm not mistaken the total outstanding shares remained the same. |
|
